Premium
Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014
Author(s) -
Weiner Michael W.,
Veitch Dallas P.,
Aisen Paul S.,
Beckett Laurel A.,
Cairns Nigel J.,
Cedarbaum Jesse,
Donohue Michael C.,
Green Robert C.,
Harvey Danielle,
Jack Clifford R.,
Jagust William,
Morris John C.,
Petersen Ronald C.,
Saykin Andrew J.,
Shaw Leslie,
Thompson Paul M.,
Toga Arthur W.,
Trojanowski John Q.
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.04.005
Subject(s) - neuroimaging , alzheimer's disease neuroimaging initiative , clinical trial , disease , medicine , depression (economics) , psychology , oncology , alzheimer's disease , psychiatry , macroeconomics , economics
The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials. Methods We searched for ADNI publications using established methods. Results ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post‐traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data‐sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public‐private partnerships developing biomarkers for Parkinson's disease and multiple sclerosis. Discussion ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials.